107 related articles for article (PubMed ID: 2302256)
1. Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-dichlorodiammineplatinum-induced cell inactivation.
Dornish JM; Pettersen EO
Biochem Pharmacol; 1990 Jan; 39(2):309-18. PubMed ID: 2302256
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives.
Dornish JM; Pettersen EO
Cancer Lett; 1989 Jul; 46(1):63-8. PubMed ID: 2736510
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.
Dornish JM; Pettersen EO; Oftebro R; Melvik JE
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1287-93. PubMed ID: 6541584
[TBL] [Abstract][Full Text] [Related]
4. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.
Dornish JM; Melvik JE; Pettersen EO
Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of cis-dichlorodiammineplatinum (II)-induced cytotoxicity by methylglyoxal.
Dornish JM; Pettersen EO
Anticancer Res; 1989; 9(4):1137-42. PubMed ID: 2817795
[TBL] [Abstract][Full Text] [Related]
6. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.
Dornish JM; Pettersen EO
Cancer Lett; 1985 Dec; 29(3):235-43. PubMed ID: 4075292
[TBL] [Abstract][Full Text] [Related]
7. Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells.
Dornish JM; Pettersen EO; Oftebro R
Cancer Res; 1989 Jul; 49(14):3917-21. PubMed ID: 2736532
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cell inactivation of human NHIK 3025 cells by cinnamaldehyde in combination with cis-diamminedichloroplatinum(II).
Dornish JM; Pettersen EO; Oftebro R
Cancer Res; 1988 Feb; 48(4):938-42. PubMed ID: 3338086
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.
Dornish JM; Pettersen EO; Oftebro R
Br J Cancer; 1987 Sep; 56(3):273-8. PubMed ID: 3663475
[TBL] [Abstract][Full Text] [Related]
10. Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro.
Dornish JM; Undheim K; Pettersen EO; Oftebro R; Laland SG
Anticancer Drug Des; 1988 Dec; 3(3):191-8. PubMed ID: 3207466
[TBL] [Abstract][Full Text] [Related]
11. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
12. In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity.
Melvik JE; Dornish JM; Larsen RO; Børretzen B; Oftebro R; Pettersen EO
Anticancer Res; 1992; 12(1):33-8. PubMed ID: 1567178
[TBL] [Abstract][Full Text] [Related]
13. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
14. 4,6-Benzylidene-D-glucose, a benzaldehyde derivative that inhibits protein synthesis but not mitosis of NHIK 3025 cells.
Pettersen EO; Dornish JM; Rønning OW
Cancer Res; 1985 May; 45(5):2085-91. PubMed ID: 3986764
[TBL] [Abstract][Full Text] [Related]
15. Effect on protein synthesis and cell survival of the benzaldehyde derivatives sodium benzylidene ascorbate (SBA) and the deuterated compound zilascorb(2H).
Pettersen EO; Larsen RO; Boerretzen B; Dornish JM; Oftebro R
Anticancer Res; 1991; 11(3):1077-81. PubMed ID: 1888141
[TBL] [Abstract][Full Text] [Related]
16. Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro.
Pettersen EO; Nome O; Rønning OW; Oftebro R
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):507-14. PubMed ID: 6683185
[TBL] [Abstract][Full Text] [Related]
17. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells.
Melvik JE; Pettersen EO; Gordon PB; Seglen PO
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1523-30. PubMed ID: 3595677
[TBL] [Abstract][Full Text] [Related]
18. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
19. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
20. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]